{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T16:55:30Z","timestamp":1783875330271,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jviromet.2021.114376","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T20:22:32Z","timestamp":1637698952000},"page":"114376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Comparison of the neutralizing activities of antibodies in clinical sera against both Sabin and wild-type polio pseudoviruses"],"prefix":"10.1016","volume":"300","author":[{"given":"Shaohua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3658-8913","authenticated-orcid":false,"given":"Xiuling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2021.114376_bib0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0092-1157(83)80031-6","article-title":"Poliovirus and polio antibody assay in Hep-2 and Vero cell cultures","volume":"11","author":"Albrecht","year":"1983","journal-title":"J. Biol. Stand."},{"issue":"8","key":"10.1016\/j.jviromet.2021.114376_bib0010","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1128\/JCM.00499-13","article-title":"Development of poliovirus extraction method from stool extracts by using magnetic nanoparticles sensitized with soluble poliovirus receptor","volume":"51","author":"Arita","year":"2013","journal-title":"J. Clin. Microbiol."},{"issue":"1","key":"10.1016\/j.jviromet.2021.114376_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48534-1","article-title":"Evaluation of antigenic differences between wild and Sabin vaccine strains of poliovirus using the pseudovirus neutralization test","volume":"9","author":"Arita","year":"2019","journal-title":"Sci. Rep."},{"issue":"Pt 11","key":"10.1016\/j.jviromet.2021.114376_bib0020","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1099\/vir.0.82172-0","article-title":"Quantitative analysis of poliomyelitis-like paralysis in mice induced by a poliovirus replicon","volume":"87","author":"Arita","year":"2006","journal-title":"J. Gen. Virol."},{"issue":"11","key":"10.1016\/j.jviromet.2021.114376_bib0025","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1128\/CVI.05225-11","article-title":"Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum","volume":"18","author":"Arita","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.jviromet.2021.114376_bib0030","first-page":"29S D80","article-title":"The global polio eradication initiative: lessons learned and prospects for success","author":"Aylward","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.jviromet.2021.114376_bib0035","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5501\/wjv.v1.i4.108","article-title":"History of polio vaccination","volume":"1","author":"Baicus","year":"2012","journal-title":"World J. Virol."},{"issue":"4","key":"10.1016\/j.jviromet.2021.114376_bib0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0166-0934(83)90046-0","article-title":"Conventional and enhanced plaque neutralization assay for polio antibody","volume":"6","author":"Boone","year":"1983","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jviromet.2021.114376_bib0045","first-page":"1","author":"CDC","year":"1997","journal-title":"46 (RR-3)"},{"issue":"RR-5","key":"10.1016\/j.jviromet.2021.114376_bib0050","first-page":"1","article-title":"Poliomyelitis prevention in the United States; updated recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"49","author":"CDC","year":"2000","journal-title":"Morbidity and mortality weekly report"},{"key":"10.1016\/j.jviromet.2021.114376_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jviromet.2016.02.010","article-title":"A rapid and quantitative assay for measuring neutralizing antibodies of coxsackievirus B3","volume":"232","author":"Chen","year":"2016","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jviromet.2021.114376_bib0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jviromet.2017.04.005","article-title":"Development of a pseudovirus based assay for measuring neutralizing antibodies against coxsackievirus B5","volume":"246","author":"Chen","year":"2017","journal-title":"J. Virol. Methods"},{"issue":"1","key":"10.1016\/j.jviromet.2021.114376_bib0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/21645515.2017.1373922","article-title":"Development and optimization of a sensitive pseudovirus-based assay for HIV-1 neutralizing antibodies detection using A3R5 cells","volume":"14","author":"Chen","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jviromet.2021.114376_bib0070","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1743-422X-4-70","article-title":"Epidemics to eradication: the modern history of poliomyelitis","volume":"4","author":"De","year":"2007","journal-title":"Virol. J."},{"issue":"8","key":"10.1016\/j.jviromet.2021.114376_bib0075","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1086\/424524","article-title":"Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy","volume":"190","author":"Dragunsky","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jviromet.2021.114376_bib0080","unstructured":"Estivariz, F., Link-Gelles, R., Shimabukuro, T., Poliomyelitis Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th Edition. Chapter 18. CDC. Updated November 2020. Accessed April 2021."},{"key":"10.1016\/j.jviromet.2021.114376_bib0085","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/infdis\/168.2.452","article-title":"Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines","volume":"168","author":"Faden","year":"1993","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.jviromet.2021.114376_bib0090","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/21645515.2018.1526553","article-title":"A simple and safe antibody neutralization assay based on polio pseudoviruses","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"issue":"15-16","key":"10.1016\/j.jviromet.2021.114376_bib0095","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0264-410X(98)00409-5","article-title":"Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains","volume":"17","author":"Kersten","year":"1999","journal-title":"Vaccine."},{"issue":"12","key":"10.1016\/j.jviromet.2021.114376_bib0100","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/jmv.24909","article-title":"A safe and reliable neutralization assay based on pseudovirus to measure neutralizing antibody titer against poliovirus","volume":"89","author":"Liu","year":"2017","journal-title":"J. Med. Virol."},{"issue":"11","key":"10.1016\/j.jviromet.2021.114376_bib0105","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1080\/21645515.2015.1011975","article-title":"The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals","volume":"11","author":"Mao","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"issue":"3","key":"10.1016\/j.jviromet.2021.114376_bib0110","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/oxfordjournals.aje.a115009","article-title":"Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines","volume":"128","author":"McBean","year":"1988","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.jviromet.2021.114376_bib0115","series-title":"Viral Pathogenesis, Lippincott-Raven Publishers, Philadelphia, Pa","first-page":"555","article-title":"Poliovirus","author":"Minor","year":"1997"},{"issue":"3","key":"10.1016\/j.jviromet.2021.114376_bib0120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/aje\/kwi033","article-title":"David Bodian\u2019s contribution to the development of poliovirus vaccine","volume":"161","author":"Nathanson","year":"2005","journal-title":"Am. J. Epidemiol."},{"issue":"5","key":"10.1016\/j.jviromet.2021.114376_bib0125","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2105\/AJPH.44.5.563","article-title":"Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines","volume":"44","author":"Salk","year":"1954","journal-title":"Am. J. Public Health Nations Health"},{"issue":"4","key":"10.1016\/j.jviromet.2021.114376_bib0130","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/risa.12019","article-title":"Preeradication vaccine policy options for poliovirus infection and disease control","volume":"33","author":"Thompson","year":"2013","journal-title":"Risk Anal."},{"issue":"1","key":"10.1016\/j.jviromet.2021.114376_bib0135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00144420","article-title":"Persistence of immunity to poliomyelitis among a southern population that received four doses of OPV 5 to over 15 years before","volume":"12","author":"Triassi","year":"1996","journal-title":"Eur. J. Epidemiol."},{"issue":"47","key":"10.1016\/j.jviromet.2021.114376_bib0140","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1016\/j.vaccine.2013.09.021","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults","volume":"31","author":"Verdijk","year":"2013","journal-title":"Vaccine"},{"issue":"39","key":"10.1016\/j.jviromet.2021.114376_bib0145","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1016\/j.vaccine.2014.07.029","article-title":"Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants","volume":"32","author":"Verdijk","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jviromet.2021.114376_bib0150","series-title":"WHO Global Action Plan to Minimize Poliovirus Facility-associated Risk After Type-specific Eradication of Wild Polioviruses and Sequential Cessation of Oral Polio Vaccine","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.jviromet.2021.114376_bib0155","series-title":"WHO Global Action Plan to Minimize Poliovirus Facility-associated Risk After Type-specific Eradication of Wild Polioviruses and Sequential Cessation of Oral Polio Vaccine Use: GAPIII","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.jviromet.2021.114376_bib0160","series-title":"Polio Endgame Strategy 2019-2023: Eradication, Integration, Certification and Containment","author":"World Health Organization & Global Polio Eradication Initiative","year":"2019"},{"issue":"9871","key":"10.1016\/j.jviromet.2021.114376_bib0165","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(12)61764-4","article-title":"Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial","volume":"381","author":"Zhu","year":"2013","journal-title":"Lancet (London, England)"}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093421003153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093421003153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T10:55:57Z","timestamp":1759056957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093421003153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":33,"alternative-id":["S0166093421003153"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2021.114376","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the neutralizing activities of antibodies in clinical sera against both Sabin and wild-type polio pseudoviruses","name":"articletitle","label":"Article Title"},{"value":"Journal of Virological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviromet.2021.114376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114376"}}